Eledon Pharmaceuticals
ELDN
75 hedge funds and large institutions have $159M invested in Eledon Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 19 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1,400% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 3
850% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 2
573% more call options, than puts
Call options by funds: $74K | Put options by funds: $11K
245% more capital invested
Capital invested by funds: $46M → $159M (+$113M)
127% more funds holding
Funds holding: 33 → 75 (+42)
17.82% more ownership
Funds ownership: 46.61% → 64.43% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.1M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$9.18M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$7.73M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.24M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.89M |
| 2 |
ZP
Zimmer Partners
New York
|
-$2.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$44.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$27.5K |
| 5 |
JP Morgan Chase
New York
|
-$242 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
76
Armistice Capital
New York
| – | -$5.89M | -2,364,000 | Closed |
|
|
TSS
77
Two Sigma Securities
New York
| – | -$27.5K | -11,027 | Closed |
|
|
78
JP Morgan Chase
New York
| – | -$242 | -97 | Closed |
|
ELDN Hedge Fund Activity: Q4 2024 in Review
75 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2024, worth a combined $159M — up 245% from $46M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ELDN positions and 3 closed out — a net gain of 42 holders — while 19 added to existing stakes and 2 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $14.1M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.89M sold.
- 75 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2024, up from 33 in Q3 2024.
- Funds reported $159M of Eledon Pharmaceuticals stock for Q4 2024, up 245% quarter-over-quarter.
- 45 funds opened new Eledon Pharmaceuticals positions in Q4 2024 and 3 closed out, a net change of +42 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2024 was RA Capital Management, an estimated $14.1M added.
- The largest Eledon Pharmaceuticals seller in Q4 2024 was Armistice Capital, an estimated $5.89M sold.
Based on aggregated 13F filings for Q4 2024.